RAP80 Antibody

Immunohistochemistry-Paraffin: RAP80 Antibody [NBP1-87156]

Immunohistochemistry-Paraffin: RAP80 Antibody [NBP1-87156] - Staining of human testis.

Immunocytochemistry/ Immunofluorescence: RAP80 Antibody [NBP1-87156]

Immunocytochemistry/Immunofluorescence: RAP80 Antibody [NBP1-87156] - Staining of human cell line U-2 OS shows localization to nucleus & nuclear bodies. Antibody staining is shown in green.

Immunohistochemistry-Paraffin: RAP80 Antibody [NBP1-87156]

Immunohistochemistry-Paraffin: RAP80 Antibody [NBP1-87156] - Staining of human cerebral cortex using Anti-UIMC1 antibody.

Immunohistochemistry-Paraffin: RAP80 Antibody [NBP1-87156]

Immunohistochemistry-Paraffin: RAP80 Antibody [NBP1-87156] - Staining of human colon using Anti-UIMC1 antibody.

Immunohistochemistry-Paraffin: RAP80 Antibody [NBP1-87156]

Immunohistochemistry-Paraffin: RAP80 Antibody [NBP1-87156] - Staining of human lymph node using Anti-UIMC1 antibody.

Immunocytochemistry/ Immunofluorescence: RAP80 Antibody [NBP1-87156] -

Immunocytochemistry/ Immunofluorescence: RAP80 Antibody [NBP1-87156] - EHMT1 & EHMT2 are required for accumulation of ubiquitin conjugates & repair factors at DNA damage sites. (a,b) Immunofluorescence analysis of U2OS cells (a) & MCF7 (b) cells transfected with indicated siRNA, & co-immunostained with indicated antibodies at 2 h after exposure to neocarzinostatin (NCS, 50 ng/ml for 15 min). A representative image of each treated or control cells is shown, as indicated. DNA damage induced foci are quantified as the percentage of cells with more than 5 large foci in nuclei after background subtraction, each based on at least 150 cells from three independent experiments (right). Error bars represent standard deviation (SD). Statistical significance was calculated using two-tailed, unpaired t-test compared with control cells; *P < 0.0001. The knockdown efficiencies with individual siRNAs against EHMT1 & EHMT2 are shown in Fig. S3a,b. Scale bar, 10 μm. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30022091), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: RAP80 Antibody [NBP1-87156] -

Immunocytochemistry/ Immunofluorescence: RAP80 Antibody [NBP1-87156] - NHEJ pathway inhibition rescue HR & cell survival in FA cells. (A) Representative images of pDNA-PKcs (red) & MRE11 (green) foci in nuclei (DAPI stained, blue) of FANCC-corrected (PD331 corr) or FANCC-mutated (PD331 FANCC−/−) cells in which 53BP1 was depleted by siRNA White line: 2 μm. (B) Histogram presents the frequency of MRE11-positive FANCC−/− cells 48 h after 53BP1 downregulation by siRNA transfection. The presented data are the mean of three independent experiments; error bars indicate S.D. *** indicates P < 0.001 using a Student's t-test. (C) Representative images of pDNA-PKcs (red), 53BP1 (green), RAP80 (red) or MRE11 (green) foci in nuclei (DAPI stained, blue) of FANCC-deficient cells (PD331 FANC−/−) treated with DMSO or with a DNA-PK specific inhibitor. The cells were treated with DNA-PK inhibitor (DNA-PKi 10 μm) for 2 h before MMC exposure (200 ng/ml). White line: 2 μm. (D & E) Clonogenic survival of FANCC-proficient (D, PD331 corr) or -mutated (E, PD331 FANCC−/−) cells after 53BP1 depletion by siRNA and/or DNA-PK inhibition. The cells were treated with MMC at the indicated doses. The presented data are the mean of three independent experiments; error bars indicate S.D. * indicates P < 0.05 using a Student's t-test. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26446986), licensed under a CC-BY license. Not internally tested by Novus Biologicals.